Approval of Myqorzo for obstructive hypertrophic cardiomyopathy and Redemplo for familial chylomicronemia syndrome Underscores Sanofi’s long-ter...
Stablepharma Limited, specialists in thermostable formulations,announced a development and option-to-license agreement with AFT Pharmaceuticals to ...
Rakuten Medical, Inc. and LOTTE Biologics announced that they have signed a biopharmaceutical contract manufacturing agreement during the J.P....
ElpasBio Holdings ("ElpasBio"), a leading clinical-stage biotechnology company focused on regenerative medicine, announced that it has entered into a col...
Jubilant Biosys Limited, a wholly owned subsidiary of Jubilant Pharmova Limited, and a global CRDMO operating from five sites across India ...
Hongene Biotech announced the receipt of a grant from the Gates Foundation to develop high-quality, affordable, and patent-free cap analogs for use ...
-ChemWerth, Inc., a global leader in generic active pharmaceutical ingredient (API) development and supply, continues to expand its footprint and strengt...
Accelerated pathway: Integrated cell line development, process development, analytics, GMP drug substance, plus drug product support through quali...
Phase 3 study met all primary and secondary endpoints, demonstrating superior convenience, strong efficacy, and excellent safety versus conventional ondans...
If approved, lecanemab may become the first and only anti-amyloid treatment in China to offer an at-home injection from the initiation of treatment for...
MDR-001 progressed from program discovery to Phase III in just 4.5 years, much faster than traditional development cycles. Phase IIb data demonstrated...
WuXi Biologics (2269.HK) announced it has achieved ISO 20400 Sustainable Procurement certification, an internationally recognized standard that integrate...
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company," 6990.HK) announced that its TROP2-directed antibody-drug ...
Samsung Bioepis completes full transfer of commercial rights from Biogen back to Samsung Bioepis for BYOOVIZ® BYOOVIZ becomes the fourth biosimi...
© 2026 Biopharma Boardroom. All Rights Reserved.
